Login to Your Account

Pozen's Second Migraine Drug, MT 100, Turned Down By FDA

By Karen Pihl-Carey

Wednesday, June 2, 2004
Pozen Inc.'s stock plummeted Tuesday on news that it received a not-approvable letter from the FDA for its migraine drug MT 100. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription